Welcome to our dedicated page for SOLESENCE SEC filings (Ticker: SLSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solésence, Inc. (Nasdaq: SLSN) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a scientifically driven health care solutions company in beauty and life science categories. These SEC filings cover its activities in mineral-based skin care, sun care and color cosmetics, as well as its broader corporate and financial structure.
On this page, investors can review Solésence’s periodic reports, such as its Form 10-K referenced in company press releases, which describe risk factors, dependence on key customers, intellectual property around engineered materials and technologies, and other aspects of its household and personal products business. Quarterly results are often accompanied by Form 8-K filings under Item 2.02, in which Solésence furnishes earnings press releases detailing revenue composition, gross profit, operating expenses and non-GAAP metrics.
Additional Form 8-K filings document material events, including leadership transitions, employment agreements with senior executives, settlements related to commercial disputes, and outcomes of the annual meeting of stockholders. Proxy materials such as the DEF 14A provide information on the company’s classified board, equity compensation plan approvals and auditor ratification, as well as voting results.
Through Stock Titan, users can access these Solésence filings as they are made available on EDGAR and use AI-powered summaries to interpret lengthy documents. The platform can highlight key points from 10-K and 10-Q reports, explain the implications of 8-K items, and surface information related to executive arrangements and shareholder approvals. Filings related to equity compensation, board structure and customer or financing arrangements are particularly relevant for understanding Solésence’s governance and its position within the consumer defensive sector.
Solésence, Inc. (SLSN) reported that a review of inventory accounting for the quarter ended June 30, 2026 identified errors in its historical accounting for labor and overhead in inventories. The company used budget-based allocation methods that were not sufficiently supported and did not fully comply with ASC 330, Inventory, including capitalization limits and overhead allocation requirements.
As a result, Solésence concluded that inventories were overstated and cost of revenue misstated, which also affected gross profit, operating income (loss), income (loss) before income taxes, net income (loss), earnings (loss) per share, accumulated deficit, total stockholders’ equity and related disclosures for multiple prior periods. On August 17, 2026, the Audit Committee, Board of Directors and Executive Officers determined that consolidated financial statements as of and for the periods ended December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025 and March 31, 2026 should no longer be relied upon and should be restated. Solésence expects to file amendments to its Annual Reports on Form 10-K for the years ended December 31, 2023, 2024 and 2025 and to its Quarterly Reports on Form 10-Q for the affected quarters, and has discussed these matters with its independent accountant.
Solésence, Inc. (SLSN) reported weaker financial results for the quarter ended June 30, 2026, while outlining strong order visibility and revenue expectations for the rest of the year. Net revenue for the second quarter was $15.3 million, down from $20.4 million a year earlier, largely due to a prior-year benefit from a major product launch and initial pipeline fill. Gross profit declined to $4.7 million with a 31% gross margin, versus $6.4 million and 32% in the second quarter of 2025. The company swung to a net loss of $158,000 from net income of $3.2 million, and adjusted EBITDA fell to $523,000 from $3.7 million.
Management also completed an evaluation of historical inventory costing allocation methodologies after filing a Form NT 10-Q and will restate related inventory valuation, emphasizing that these adjustments affect accounting presentation rather than cash generation or operations. As of August 17, 2026, shipped and on-hand orders for 2026 totaled $64.9 million, up from $60.0 million at the same point in 2025. The company expects sequential improvement in the third quarter, projects approximately $35 million of revenue in the second half of 2026, and believes full-year 2026 revenue will exceed 2025.
Solésence, Inc. (SLSN) reported sharply lower sales and a loss for the quarter ended June 30, 2026, while disclosing a major accounting restatement and a material weakness in internal controls. Quarterly revenue was $15.3 million, down from $20.4 million a year earlier, and the company posted a net loss of $0.2 million versus net income of $3.2 million in 2025. For the first half of 2026, revenue was $28.3 million, down from $35.0 million, and the net loss was $1.1 million versus prior-year income of $3.6 million.
Despite weaker earnings, Solésence generated $1.7 million of operating cash flow in the first half of 2026 compared with a $7.9 million use of cash a year earlier, ending June with $1.0 million of cash and $46.4 million in total assets. Three customers accounted for 66% of second-quarter revenue and $7.7 million of receivables, underscoring significant customer concentration. Related-party borrowings with affiliates of a major shareholder totaled about $14.3 million, with facilities maturing in 2027.
Management found that historical inventory costing did not comply with ASC 330, causing inventory and equity to be overstated. As a result, multiple prior-year financial statements can no longer be relied upon and are being restated; December 31, 2025 inventory was reduced by $3.5 million and accumulated deficit increased by the same amount. The quarter’s statements were prepared using corrected methods, but the independent auditor had not completed its review as of filing. The company also recorded a $0.9 million settlement liability tied to a dispute with Refy Beauty and acknowledged a material weakness in internal control over inventory accounting, with remediation efforts underway.
Solésence, Inc. (formerly Nanophase Technologies Corporation) notified investors that it will file its Form 10-Q for the quarter ended June 30, 2026 after the prescribed deadline. The company is relying on the short filing extension available under Rule 12b-25.
The company disclosed that it recently discovered it had applied an improper inventory costing methodology and is determining appropriate corrective measures and the amount of the anticipated change to its results. Management also cautioned that forward-looking statements about the expected timing of the Form 10-Q filing are subject to risks, including the possibility that additional or different information may emerge before the report is filed.
Solésence, Inc., through its wholly owned subsidiary Solésence, LLC, entered into a Settlement Agreement and Release with Refy Beauty Ltd to resolve disputes over certain consumer care products previously sold to Refy. Solésence agreed to pay Refy the British Pound Sterling equivalent of $938,000 in twelve equal installments of $78,166.66, with the first payment due on August 5, 2026 and each subsequent payment due 30 days later. The parties also agreed to a six month exclusivity period for development of a new SPF product and potential negotiation of a new supply agreement. If a new supply agreement is executed, the final six scheduled installment payments would instead be credited toward purchases of the SPF product under that supply agreement.
Solésence, Inc. reported a net loss for the quarter ended March 31, 2026 as revenue declined. Total revenue was $12,957 (in thousands), down from $14,625 (in thousands) a year earlier, driven by lower consumer products and advanced materials sales, partly offset by higher personal care ingredients revenue.
Gross profit was $3,337 (in thousands), roughly flat versus $3,382 (in thousands), but higher selling, general and administrative expenses of $2,799 (in thousands) and research and development of $1,042 (in thousands) contributed to a net loss of $766 (in thousands), compared with net income of $80 (in thousands) in 2025.
Operating cash flow improved to $1,517 (in thousands) from a use of $7,221 (in thousands), aided by working capital changes. Cash decreased to $573 (in thousands) as of March 31, 2026, while related-party borrowings remained significant, including a $9,500 (in thousands) inventory facility and $3,047 (in thousands) drawn on an accounts receivable line.
Solésence, Inc. reported first quarter 2026 revenue of $13.0 million, down from $14.6 million a year earlier, as it invested in its Transform and Transcend operational initiative. Despite lower sales, gross profit was $3.3 million and gross margin improved to 26% from 23%.
The company posted a net loss of approximately $0.8 million for the quarter, compared with net income of about $0.08 million in 2025, and Adjusted EBITDA declined to $(0.1) million from $0.6 million. Management highlighted near-term profitability pressure from training and organizational restructuring, but expects efficiency gains and lower labor costs to support better results later in the year.
Solésence, Inc. announced that its Board of Directors appointed Marc James as a Class II independent director, effective April 24, 2026. He will serve for the remainder of the Class II term, ending at the 2026 Annual Meeting of Shareholders.
James joins the Board’s Audit and Finance, Compensation, and Nominating and Corporate Governance Committees. The company highlights his capital markets and strategic experience as support for its Transform & Transcend strategic initiative and long-term growth objectives.
Solésence, Inc. filed Amendment No. 1 to its annual report to add Exhibit 97.1, which was inadvertently omitted from the original filing. The company states that no other items are being revised and the amendment does not reflect events after the original report.
The aggregate market value of voting stock held by non‑affiliates was $27,254,231 as of June 30, 2025, and 70,632,445 common shares were outstanding as of March 30, 2026. The filing also lists numerous previously filed material contracts, loan agreements, employment agreements, and the Solésence 2025 Equity Compensation Plan as exhibits.
Solésence, Inc. reports strong 2025 growth as it advances its rebranding from Nanophase Technologies into a skin-health focused consumer products company. Total revenue rose to $62,064, driven mainly by prestige beauty consumer products built on its Active Stress Defense™ technology and mineral-based UV protection APIs.
The company increasingly prioritizes finished “white label” and custom skin-care products over legacy advanced materials, operates two FDA-registered, ISO-certified facilities near Chicago, and invests heavily in R&D and capacity to meet what management describes as unprecedented demand from brand partners.